| Clinical data | |
|---|---|
| Other names | BAY1158061; HMI-115; HMI115 |
| Routes of administration | Subcutaneous injection [1] |
| Drug class | Prolactin receptor monoclonal antibody |
| ATC code |
|
| Pharmacokinetic data | |
| Elimination half-life | 9–16 days [2] |
BAY-1158061, also known as HMI-115, is a monoclonal antibody against the prolactin receptor (PRLR) which is under development for the treatment of alopecia and endometriosis. [1] [3] It is taken by long-lasting subcutaneous injection. [1] [2] BAY-1158061 has been reported to promote hair growth in balding stump-tailed macaques. [4] The drug was first described in the scientific literature by 2018. [2] [5] [4] It is under development by Bayer and Hope Medicine. [1] [3] As of June 2025, BAY-1158061 is in phase 2 clinical trials for alopecia and endometriosis. [1] [3] Multiple phase 2 trials have been completed, including trials for both alopecia and endometriosis. [1] The chemical structure of BAY-1158061 does not yet appear to have been disclosed. [1]